![]() |
市場調查報告書
商品編碼
1603754
到 2030 年水微生物檢測市場預測:按產品類型、病原體類型、水類型、最終用戶和地區進行的全球分析Microbiological Testing of Water Market Forecasts to 2030 - Global Analysis By Product Type, Pathogen Type, Water Type, End User and by Geography |
根據 Stratistics MRC 的數據,2024 年全球水微生物檢測市場規模為 19.6 億美元,預計在預測期內將以 9.4% 的複合年成長率成長,到 2030 年達到 33.6 億美元。
水的微生物檢測是評估水質並確保人類飲用、工業使用和環境保護安全的重要過程。此測試可識別和測量可能引起水傳播感染疾病並造成嚴重健康風險的微生物,例如細菌、病毒和原生動物。大腸桿菌和大腸桿菌等重要標記物經常被追蹤,因為它們可以表明糞便或其他危險源的污染。此外,微生物水測試在需要嚴格品質標準的環境中至關重要,例如市政供水系統和食品和飲料製造。
根據美國環保署 (EPA) 的規定,《安全飲用水法案》要求公共供水系統含有大腸桿菌群,以保護依賴公共飲用水系統的 3 億多美國人,並要求定期進行微生物檢測。 :
增加有關水傳播感染疾病的知識
隨著水傳播感染疾病在全球的流行,人們對水質重要性的認知不斷增強。特別是霍亂、傷寒和甲型肝炎等疾病可能對弱勢族群的健康造成毀滅性影響。隨著社區越來越意識到這些風險,對微生物檢測以確保飲用水安全且不含病原體的需求正在增加。此外,這種認知的提升也是旨在預防疾病爆發的健康措施和教育宣傳活動的結果。
測試成本高
檢測方法和檢測設備成本高昂是水微生物檢測市場的主要障礙之一。這些需要大量的初始投資,但流式細胞技術和聚合酵素鏈鎖反應(PCR) 等先進技術可提高速度和準確性。小型企業和組織,尤其是開發中國家的小型企業和組織,可能會發現很難負擔這些昂貴的測試解決方案。這可能會限制市場進入並降低採用率。此外,複雜檢測設備的持續維護和校準可以減少微生物檢測設施的投資並進一步增加營運成本。
即時監控解決方案需求
人們對水安全意識的增強以及對污染事件快速反應機制的需求正在推動對即時監控解決方案的需求。正在開發基於人工智慧的分析和自動測試設備等技術,以提高資料準確性並加快測試過程。例如,為了提高吞吐量並減少錯誤,自動化系統可以在幾乎不需要人工幫助的情況下收集和分析水樣本。此外,除了改善公共健康和安全之外,即時監測還符合及時報告水質問題的法律義務。
改變微生物的特性
微生物不斷變化的性質是微生物檢測市場的最大威脅之一。由於病原體不斷變化和適應,可能會出現使用目前檢測方法難以識別的新菌株。這需要不斷調整和改進測試方法,這需要實驗室和測試設施的成本和資源。此外,如果不適應這些變化,可能會導致未被發現的污染,使公眾健康面臨風險,並削弱人們對檢測結果的信心。
COVID-19 對水微生物檢測市場產生了複雜的影響,既帶來了機遇,也帶來了挑戰。最初,疫情擾亂了實驗室和供應鏈的業務,導致檢測服務延遲和水質評估積壓。然而,大流行引起的對健康和安全的日益關注,急劇增加了公眾對水質的擔憂,導致對微生物檢測以確保飲用水安全的需求增加。為了應對疫情,監管機構也加強了對水質標準的審查,這推動了市場。
預計大腸菌群在預測期內將達到最大值
預計水微生物檢測市場將佔據大腸桿菌群的最大佔有率。大腸桿菌群測試對於確保安全飲用水至關重要,因為它經常被用作水質和可能污染的指標。許多測試是在公共和私人自來水中進行的,因為如果存在大腸桿菌,則也可能存在其他危險的病原體。此外,隨著公眾對水傳播感染疾病的認知提高和法律規範收緊,大腸桿菌預計將繼續保持其市場主導,這凸顯了微生物在水質評估中的重要作用。
預計製藥和生物技術產業在預測期內複合年成長率最高
製藥和生物技術產業預計將以最高的複合年成長率成長。藥品生產過程中對水質的嚴格監管要求是這一成長的關鍵驅動力,其中純度和污染控制至關重要。由於微生物污染可能威脅患者安全和產品完整性,因此製藥業主要依靠微生物檢測來確保藥品生產中使用的水符合安全標準。此外,人們對生物製藥和個人化醫療的興趣日益濃厚,因此更加重視品管措施,例如對製造和研究中使用的水進行嚴格的測試程序。
由於基礎設施完善以及有關水安全和品質的嚴格法規,北美地區在水微生物檢測市場中佔據最大佔有率。包括市政供水、食品和飲料以及藥品在內的各個領域對遵守微生物檢測的強烈需求反映了在這個新興市場確保安全飲用水的重要性。此外,該地區的優勢還在於其高度發展的技術力。因為企業不斷投資尖端檢測技術以提高效率和準確性。
水微生物檢測市場預計將以歐洲地區最高的複合年成長率成長。這是由於各行業對微生物檢測設備和套件的需求不斷增加,特別是在食品和飲料、製藥和工業加工領域。由於歐洲藥品管理局 (EMA) 對藥品生產中的水質製定了嚴格的合規要求,因此可靠的測試解決方案比以往任何時候都更加重要。此外,歐盟改善清潔飲用水供應和提高公眾水安全意識的措施正在推動市場擴張。
According to Stratistics MRC, the Global Microbiological Testing of Water Market is accounted for $1.96 billion in 2024 and is expected to reach $3.36 billion by 2030 growing at a CAGR of 9.4% during the forecast period. Microbiological testing of water is a critical process used to assess water quality and ensure it is safe for human consumption, industrial use, and environmental protection. This testing entails identifying and measuring microorganisms that can cause waterborne illnesses and present significant health risks, including bacteria, viruses, and protozoa. Important markers, such as coliform bacteria and Escherichia coli (E. coli), are frequently tracked because they may indicate contamination from feces or other dangerous sources. Moreover, microbiological water testing is crucial in environments where strict quality standards are required, such as municipal water systems and food and beverage production.
According to the Environmental Protection Agency (EPA), the Safe Drinking Water Act mandates that public water systems perform regular microbiological testing for contaminants such as coliform bacteria, as part of efforts to protect over 300 million Americans who rely on public drinking water systems.
Increasing knowledge of waterborne illnesses
Public awareness of the significance of water quality has increased as a result of the rising prevalence of waterborne illnesses worldwide. Particularly in susceptible groups, diseases like cholera, typhoid fever, and hepatitis A can have catastrophic health consequences. The need for microbiological testing to guarantee that drinking water is safe and pathogen-free is growing as communities become more aware of these dangers. Additionally, this increased awareness is also a result of health initiatives and educational campaigns that try to prevent disease outbreaks.
High testing costs
The high expense of testing methods and equipment is one of the main barriers to the market for microbiological testing of water. Although they require a large initial investment, advanced technologies like flow cytometry and polymerase chain reaction (PCR) provide increased speed and accuracy. Smaller businesses and organizations might find it difficult to pay for these pricey testing solutions, especially in developing nations. As a result, market participation may be restricted and adoption rates may be slower. Furthermore, investment in microbiological testing facilities may be discouraged by the continued maintenance and calibration of complex testing apparatus, which raises operating costs even more.
Demand for monitoring solutions in real time
Growing water safety awareness and the need for rapid response mechanisms to contamination events have led to an increase in demand for real-time monitoring solutions. Technologies are being developed to improve data accuracy and expedite the testing process, including AI-driven analytics and automated testing devices. To increase throughput and decrease errors, automated systems, for example, can gather and analyze water samples with little assistance from humans. Moreover, besides improving public health and safety, this move to real-time monitoring also complies with legal mandates for prompt reporting of water quality problems.
Changing character of microorganisms
The constantly changing nature of microorganisms is one of the biggest threats to the market for microbiological testing. Because pathogens are always changing and adapting, new strains may appear that are difficult for current testing methods to identify. This calls for constant testing method adaptation and improvement, which can be expensive and resource-intensive for labs and testing facilities. Additionally, failure to adapt to these changes may lead to contamination that goes unnoticed, endangering public health and eroding trust in test results.
COVID-19 has had a complex effect on the market for microbiological testing of water, posing both opportunities and challenges. Initially, the pandemic disrupted laboratory and supply chain operations, leading to delays in testing services and a backlog of water quality assessments. However, the pandemic's increased focus on health and safety led to a sharp rise in public anxiety about water quality, which in turn fuelled demand for microbiological testing as people looked for guarantees regarding the safety of their drinking water. In reaction to the pandemic, regulatory agencies also increased their scrutiny of water quality standards, which helped to drive the market.
The Coliform segment is expected to be the largest during the forecast period
The market for microbiological testing of water is expected to be the largest share in the coliform segment. Testing for coliform bacteria is essential to guaranteeing safe drinking water because they are frequently used as an indicator of water quality and possible contamination. Numerous tests are conducted on both public and private water supplies because the presence of coliforms raises the possibility of the presence of other dangerous pathogens. Moreover, the coliform segment is anticipated to continue to hold its market leadership as public awareness of waterborne illnesses rises and regulatory frameworks become stricter, highlighting its critical role in microbial water quality assessment.
The Pharmaceutical and Biotechnology segment is expected to have the highest CAGR during the forecast period
The pharmaceutical and biotechnology segment is anticipated to grow at the highest CAGR. The strict regulatory requirements for water quality in pharmaceutical manufacturing processes, where purity and contamination control are crucial, are the main driver of this growth. Since any microbial contamination can jeopardize patient safety and product integrity, the pharmaceutical industry mainly depends on microbiological testing to make sure that water used in drug production satisfies safety standards. Additionally, a stronger emphasis on quality control measures, such as stringent testing procedures for water used in production and research, has also resulted from the growing interest in biopharmaceuticals and personalized medicine.
Due to its established infrastructure and strict regulations pertaining to water safety and quality, the North American region commands the largest share of the market for microbiological testing of water. Strong compliance requirements for microbiological testing across a range of sectors, including municipal water supplies, food and beverage, and pharmaceuticals, reflect the importance of ensuring safe drinking water in this developed market. Furthermore, the region's dominance is also a result of its highly developed technological capabilities, as businesses consistently invest in cutting-edge testing techniques to improve efficiency and accuracy.
The market for microbiological testing of water is expected to grow at the highest CAGR in the Europe region due to the growing need for microbiological testing equipment and kits in a variety of industries, especially in the food and beverage, pharmaceutical, and industrial processes sectors. Reliable testing solutions are more important than ever because of the European Medicines Agency's (EMA) stringent compliance requirements for water quality in pharmaceutical production. Moreover, the EU's efforts to increase access to clean drinking water and increased public awareness of water safety are driving market expansion.
Key players in the market
Some of the key players in Microbiological Testing of Water market include 3M Company, Agilent Technologies, Inc, Charles River Laboratories, Inc., IDEXX Laboratories, Inc., Thermo Fisher Scientific, Inc., Avantor Inc., Merck KGaA, Shimadzu Corporation, LaMotte Company, Danaher Corporation, Bio-Rad Laboratories Inc., Perkinelmer, Inc, Accepta Ltd, Dohler Group and Eurofins Scientific SE.
In August 2024, Avantor has announced a definitive agreement to divest its clinical services business to Audax Private Equity for approximately $650 million. This strategic move aims to optimize Avantor's portfolio and sharpen its focus on lab and production businesses. The transaction, expected to close in Q4 2024, will generate about $475 million in after-tax cash proceeds, which will be used for debt paydown.
In July 2024, Agilent Technologies Inc. announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
In February 2023, Thermo Fisher Scientific Inc. entered into a definitive agreement to acquire CorEvitas, a provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity, for $912.5 million in cash. CorEvitas will become part of Thermo Fisher's Laboratory Products and Biopharma Services segment. The transaction is expected to be completed by the end of 2023.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.